Biosimilar Newsletter Archive

  1. 09.16.26 -- Smarter Ways To Reduce Risk, Downtime, And Lifecycle Surprises 9/16/2026

    09/16/26 Biosimilar Development Newsletter

  2. 09.10.26 -- U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing 9/10/2026

    09/10/26 Biosimilar Development Newsletter

  3. 09.03.26 -- Why Trusted Data Is A Process Variable in Bioprocessing 9/3/2026

    09/03/26 Biosimilar Development Newsletter

  4. 08.27.26 -- The Missing Piece In Biosimilar Adoption 8/27/2026
    08/27/26 Biosimilar Development Newsletter
  5. 08.20.26 -- Exploring Takeda's Template For Sustainable Steam Generation 8/20/2026
    08/20/26 Biosimilar Development Newsletter
  6. 08.13.26 -- When Innovation Meets Scale 8/13/2026
    08/13/26 Biosimilar Development Newsletter
  7. 08.13.26 -- Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis 8/13/2026
    08/13/26 Biosimilar Development Newsletter
  8. 08.06.26 -- Achieving Annex 1 Compliance In Sterile Manufacturing 8/6/2026
    08/06/26
  9. 07.30.26 -- FDA Explains How To Respond To Form 483 Observations 7/30/2026
    07/30/26 Biosimilar Development Newsletter
  10. 07.23.26 -- Solving Glycoengineering Challenges Could Begin At The Cell Line 7/23/2026
    07/23/26